ELI LILLY & Co — Director's Dealing 2014

Nov 12, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Coherus BioSciences, Inc. (CHRS)
CIK: 0001512762
Period of Report: 2014-11-12

Reporting Person: LILLY ELI & CO (Former 10% Owner)
Reporting Person: Lilly Ventures Fund I LLC (Former 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-11-12	Common Stock, $0.0001 par value	C	2333955	—	Acquired	2333955	Direct
2014-11-12	Common Stock, $0.0001 par value	C	543101	—	Acquired	2877056	Direct
2014-11-12	Common Stock, $0.0001 par value	P	164963	$13.50	Acquired	3042019	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-11-12	Series B Preferred Stock	$	C	2333955	Disposed		Common Stock (2333955)	Indirect
2014-11-12	Series C Preferred Stock	$	C	543101	Disposed		Common Stock (543101)	Indirect

Footnotes

F1: The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering.

F2: These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund.

F3: Lilly Ventures Fund I LLC purchased an additional 164,963 shares of Issuer's Common Stock in connection with the IPO at the offering price of $13.50 per share.

F4: The Series B Preferred Stock and Series C Preferred Stock have no expiration date.